The U.S. Food and Drug Administration approved Bristol Myers Squibb Co.’s combination therapy for previously untreated patients with a form of lung cancer, a much-needed boost as the company battles the dominance of Merck’s Keytruda.

As the mortality figures for COVID-19 continued to rise, people are wondering where they will stop. The actual death toll for COVID-19 will not be calculable for some time, but there are early indications that the mortality rate may be significantly lower than calculations of deaths per confirmed cases lead one to believe.

Geneius Biotechnology is developing T cells as a quasi-personalized, off-the-shelf, therapy and preventive measure against COVID-19.

As the COVID-19 pandemic spreads around the world, researchers and public health experts are casting about for older vaccines and antiviral drugs that might be used to treat the disease caused by the novel coronavirus SARS-CoV-2. Researchers in Australia are studying an older treatment, a vaccine once used to prevent tuberculosis called the bacillus Calmette-Guerin (BCG), which has been used for about 100 years.

U.S. regulators approved AstraZeneca’s Imfinzi treatment for use against an aggressive type of lung cancer in previously untreated patients.

Sanofi and Regeneron Pharmaceuticals expanded a clinical trial of the companies’ rheumatoid arthritis drug Kevzara as a coronavirus treatment to patients outside the United States.

Repertoire Immune Medicines officially launched following the merger of two complementary Flagship Pioneering companies, Torque Therapeutics and Cogen Immune Medicines. The new company is focused on tapping into the powers of the immune system to address numerous diseases.

Intellia Therapeutics is focused on implementing a full-spectrum genome editing approach, as the company has a pipeline spanning both in vivo and ex vivo therapies to address severe and life-threatening diseases.

Dragonfly Therapeutics and AbbVie forged a multi-target research collaboration to advance new treatment options for autoimmune and oncology indications.

Eli Lilly and Co.’s experimental pancreatic cancer treatment in combination with chemotherapy drugs failed to meet the main goal of overall survival in a late-stage study.